Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer

International Journal of Cancer

Volumn 98, Issue 4, 2002, Pages 582-589

  Jensen, Benny Vittrup ^a,d   Johansen, Julia Sidenius ^b   Skovsgaard, Torben ^a   Brandt, Jette ^c   Teisner, Børge ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Advanced breast cancer; Amino terminal propeptide of type I procollagen; Collagen metabolism; Extracellular matrix; Prognostic factors; Survival

Indexed keywords

ANTHRACYCLINE; PROCOLLAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; EXTRACELLULAR MATRIX; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; PROCOLLAGEN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0036533617     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10187     Document Type: Article

References (35)

1. Collagen: Structure, function and metabolism in normal and fibrotic tissues
2. Quantification of the N-terminal propeptide of human procollagen type I (PINP): Comparison of ELISA and RIA with respect to different molecular forms
3. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology
4. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval and hypovitaminosis D-induced hyperparathyroidism
5. Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid: Preliminary observations in fetal and maternal tissues
6. Fetal antigen 2: An amniotic protein identified as the aminopropeptide of the alpha 1 chain of human procollagen type I
7. Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid: Localization in the fetus and adult female genital tract
8. Foetal antigen 2 (FA2) in relation to wound healing and fibroblast proliferation
9. Fetal antigen 2 (FA2) in human fetal osteoblasts, cultured osteoblasts and osteogenic osteosarcoma cells
10. Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts, normal human serum and serum from patients with chronic renal failure
11. Localization of foetal antigen 2 (FA-2) in foetal and adult human skin
12. Immunohistochemical studies on the localization of fetal antigen 2 (FA2), laminin and collagen type 4 in basal cell carcinoma
13. Fetal antigen 2 in primary and secondary brain tumors
14. Fetal antigen 2 (FA2) in the stromal reaction induced by breast carcinoma
15. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma
16. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer
17. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP
18. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer
19. Type I collagen metabolites as tumor markers in patients with lung carcinoma
20. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer
21. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer
22. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer
23. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
24. Stromal reaction in cancer tissue: Pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions
25. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
26. Markers of type I and type III collagen synthesis in serum as indicators of tissue growth during pregnancy
27. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
28. Changing views of the role of matrix metalloproteinases in metastasis
29. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma
30. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway
31. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
32. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
33. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women
34. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients
35. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells